Business description: Indivior Pharmaceuticals, Inc.

Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.

Other Pharmaceuticals

Change 5d. change 1-year change 3-years change Capi.($)
+0.72%-5.86%+13.89%+218.81% 885B
+0.32%-3.23%+44.22%+56.01% 579B
-0.96%-0.85%+7.38%+50.47% 407B
-2.93%-7.03%+11.14%+27.55% 350B
-1.25%-5.55%+22.14%+55.83% 302B
-1.85%-6.70%+20.11%+33.64% 301B
-0.24%-6.49%+22.33%+4.06% 286B
+0.53%-4.80%+13.75%+61.56% 199B
-0.83%-3.37%+22.59%+79.29% 179B
Average -0.72%-4.69%+19.73%+65.25% 387.64B
Weighted average by Cap. -0.47%-4.59%+20.27%+89.09%
Trader
Investor
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
32.27USD
Average target price
46.86USD
Spread / Average Target
+45.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. INDV Stock
  4. INDV Stock
  5. Company Indivior Pharmaceuticals, Inc.